COMMUNIQUÉS West-GlobeNewswire

Alberta Cancer Foundation announces initial investment of its novel philanthropic Breakthrough Fund to support early-stage cancer research
23/01/2024
Entos Pharmaceuticals and 48Hour Discovery named as first recipients of Breakthrough Fund EDMONTON, Alberta, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The Alberta Cancer Foundation is thrilled to announce that Entos [...]
Industry-Recognized Technology Leader Joins DLH as Strategic Advisor
23/01/2024
ATLANTA, Jan. 23, 2024 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital transformation and cybersecurity, science research and development, and systems [...]
Privia Health to Report Fourth Quarter and Full-Year 2023 Results on Tuesday, February 27
23/01/2024
ARLINGTON, Va., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it plans to release financial results for its fourth quarter and full year ended December 31, 2023 before [...]
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
23/01/2024
- University of Utah Hospital, Lori Gawron, M.D. of the Obstetrics and Gynecology (OB/GYN) Department, was an instrumental investigator in Femasys’ earlier FemBloc study - - FemBloc is being developed as a first-of-its- [...]
Alkeus Pharmaceuticals Appoints Seemi Khan, M.D., Chief Medical Officer
23/01/2024
CAMBRIDGE, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that Seemi Khan, M.D., M.P.H., M.B.A., has joined the Company as Chief Medical Officer. “We are thrilled to welcome Dr. [...]
Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
23/01/2024
SOLANA BEACH, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
23/01/2024
HOUSTON, TX, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. [...]
Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica
23/01/2024
Mr. Kenny has significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Kenny most recently served as CEO of Meridian Bioscience where he successfully built and ultimately [...]
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
23/01/2024
Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer along with [...]
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
23/01/2024
REDWOOD CITY, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare [...]
Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE® 327 for the Treatment of Diabetic Foot Infections
23/01/2024
Phase I/II trial assessing the safety and efficacy of RECCE ® 327 (R327), a broad-spectrum anti-infective as a topical treatment, met all primary endpoints R327 was well-tolerated in all patients, resolving mild skin [...]
NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)
23/01/2024
NAYA to accelerate Phase II clinical development and Early Patient Access after initial safety demonstrated in 28-patient clinical trial Program developed by Florida Biotechnologies, Inc. & the University of Miami’s [...]
InnovAge to Announce Fiscal Second Quarter 2024 Financial Results and Host Conference Call Tuesday, February 6, 2024
23/01/2024
DENVER, Jan. 23, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible [...]
PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application
23/01/2024
MINNEAPOLIS, MN, Jan. 23, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices [...]
Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts
23/01/2024
Pharmaloz Wins Two New Contracts in January that are Anticipated to Significantly Increase Lozenge Revenues and Profitability Company in Late-Stage Discussions with Two Additional Large Global Brands Which, if [...]
Sensus Healthcare Announces Preliminary 2023 Revenue Exceeds $23 Million
23/01/2024
Ships more than 60 SRT units in 2023 To report full financial results and hold conference call on February 8 th BOCA RATON, Fla. , Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS ), a medical [...]
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
23/01/2024
4D-710 has demonstrated promising, reproducible, CFTR expression significantly above normal levels for seven patients across Cohorts 1 & 2 (1E15-2E15 vg) and durable improvement or stabilization of quality of life [...]
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010
23/01/2024
Obtained clarity from U.S. Food and Drug Administration (FDA) on next steps to advance ONS-5010 NORSE EIGHT expected to commence in the first quarter of CY2024, enabling potential resubmission of the ONS-5010 Biologics [...]
Bionano Announces Full Commercial Release of the Stratys™ System for High Throughput Optical Genome Mapping
23/01/2024
Bionano has completed the early access program for the Stratys™ system and is now making it available in a full commercial release The Stratys instrument can enable up to a four-fold increase in raw data generation rate [...]

Pages